Breye Therapeutics Reports Completion of Phase 1b for Oral NPDR Therapy

Breye Therapeutics reports completion of phase 1b for oral NPDR therapy

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

Successful phase 1B study of oral therapy for diabetic retinopathy

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy – Optimum Strategic CommunicationsLink to: Atrogi announces Cell paper highlighting transformative potential of muscle-targeted

Orally administered treatment was well tolerated, with early signs of clinical activity In models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal capillary loss and vascular leakage Data support continued advancement into Phase 2 clinical evaluation Copenhagen, Denmark, 24 June 2025 – Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology focused biopharmaceutical company […]